相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clopidogrel-associated genetic variants on inhibition of platelet activity and clinical outcome for acute coronary syndrome patients
Xiaoye Li et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2019)
Association of PON1 gene promoter DNA methylation with the risk of Clopidogrel resistance in patients with coronary artery disease
Jia Su et al.
JOURNAL OF CLINICAL LABORATORY ANALYSIS (2019)
Influence of CYP450 Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel Response in Patients Subjected to a Percutaneous Neurointervention
Miriam Saiz-Rodriguez et al.
CLINICAL THERAPEUTICS (2019)
Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis
Shang-He-Lin Yin et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China
Zhixiong Zhong et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Phenotyping of CYP 4501A2 Activity by Total Overnight Salivary Caffeine Assessment (TOSCA) in Patients on Warfarin Treatment: A Cross-Sectional Study
Giovanni Tarantino et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2018)
Association of CYP2C19*2 polymorphism with clopidogrel response and 1-year major adverse cardiovascular events in a multiethnic population with drug-eluting stents
Shirley Siang Ning Tan et al.
PHARMACOGENOMICS (2017)
Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients
J. F. M. Marchini et al.
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH (2017)
Does i-T744C P2Y12 Polymorphism Modulate Clopidogrel Response among Moroccan Acute Coronary Syndromes Patients?
Hind Hassani Idrissi et al.
GENETICS RESEARCH INTERNATIONAL (2017)
Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome
You-quan Wei et al.
PLOS ONE (2015)
Effects of Cytochrome P450 2C19 and Paraoxonase 1 Polymorphisms on Antiplatelet Response to Clopidogrel Therapy in Patients with Coronary Artery Disease
Damrus Tresukosol et al.
PLOS ONE (2014)
Effect of the CYP2C19*2 and *3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention
Xiao-Fang Tang et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Paraoxonase 1 Gene Polymorphism Does Not Affect Clopidogrel Response Variability but Is Associated with Clinical Outcome after PCI
Kyung Woo Park et al.
PLOS ONE (2013)
Relationship of CYP2C19*2 and CYP2C19*3 Gene Polymorphism with Clopidogrel Response Variability and Recurrent Cardiovascular Events in Chinese Patients Undergoing Percutaneous Coronary Intervention
Yamin Liu et al.
PHARMACOLOGY (2013)
Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood
Ersin Gumus et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents
Il-Young Oh et al.
HEART (2012)
Paraoxonase-1 Is Not a Major Determinant of Stent Thrombosis in a Taiwanese Population
Dong-Yi Chen et al.
PLOS ONE (2012)
CYP2C19 But Not PON1 Genetic Variants Influence Clopidogrel Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy in Post-Myocardial Infarction Patients
Jean-Sebastien Hulot et al.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2011)
No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting
Dirk Sibbing et al.
EUROPEAN HEART JOURNAL (2011)
High Residual Platelet Reactivity After Clopidogrel Loading and Long-term Cardiovascular Events Among Patients With Acute Coronary Syndromes Undergoing PCI
Guido Parodi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Influence of high-density lipoprotein and paraoxonase-1 on platelet reactivity in patients with acute coronary syndromes receiving clopidogrel therapy
A. D. Tselepis et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)
Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study
P. Fontana et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)
Paraoxonase-1 is a major determinant of clopidogrel efficacy
Heleen J. Bouman et al.
NATURE MEDICINE (2011)
Relation of Genetic Polymorphisms in the Cytochrome P450 Gene With Clopidogrel Resistance After Drug-Eluting Stent Implantation in Koreans
Jung Myung Lee et al.
AMERICAN JOURNAL OF CARDIOLOGY (2009)
Impact of CYP2C19 Polymorphisms on the Antiplatelet Effect of Clopidogrel in an Actual Clinical Setting in Japan
Toshikazu Jinnai et al.
CIRCULATION JOURNAL (2009)
Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
Alan R. Shuldiner et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents
Dietmar Trenk et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Impact of P-glycoprotein on clopidogrel absorption
Dirk Taubert et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Cytochrorne P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
Jean-Sebastien Hulot et al.
BLOOD (2006)
Resistance to clopidogrel: A review of the evidence
TA Nguyen et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
分享论文
